Hormonal therapy for epithelial ovarian cancer.
Despite the fact that hormonal therapy has been employed in the management of ovarian cancer for more than 40 years, there is limited information available in the peer-reviewed medical literature to document the beneficial impact of the strategy, either on improvement in cancer-related symptoms or prolongation of survival. Existing data suggest that approximately 5-10% of ovarian cancer patients treated with a hormone-based strategy in the second-line setting will achieve evidence of substantial tumor shrinkage, with a larger proportion of individuals likely to demonstrate stabilization of the disease process for a highly variable time interval. The major advantage with the use of hormonal treatments is the well-recognized and highly favorable toxicity profile associated with this class of antineoplastic agents.
The University of Texas M.D., Anderson Cancer Center (Mail Box #121), 1515 Holcombe Boulevard, Houston, Texas 77030, USA. markman@manderson.org.
Maurie
M
Markman